Letter to the Editor Regarding "Natalizumab-Associated Primary Central Nervous System Lymphoma"

World Neurosurg. 2018 Jul:115:473-474. doi: 10.1016/j.wneu.2018.01.159.

Authors

Daniele Sartori¹, Birgitta Grundmark²

Affiliations

¹ World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, Uppsala, Sweden. Electronic address: daniele.sartori@who-umc.org.
² World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, Uppsala, Sweden; Department of Surgery, Uppsala University, Uppsala, Sweden.

PMID: 29958368
DOI: 10.1016/j.wneu.2018.01.159

No abstract available

Publication types

Letter
Comment

MeSH terms

Central Nervous System
Central Nervous System Neoplasms*
Humans
Lymphoma, Non-Hodgkin
Natalizumab*

Substances

Natalizumab